Olema Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company based in San Francisco that develops targeted therapies for women's cancers, especially breast cancer. Its lead drug candidate, palazestrant (OP-1250), is an oral pill designed to block the estrogen receptor that fuels many breast tumors, offering patients a daily-at-home option instead of an injection. Founded in 2016, the company went public in 2020 to fund its clinical trials.
Sold 41.4K
Granted 100.0K · Sold 161.0K
Granted 35.9K
Sold 103.8K
Granted 140.0K · Sold 269.5K
Granted 11.7K
Granted 40.0K · Sold 40.0K
Granted 264.8K · Sold 264.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Harmon CyrusDirector · 7 transactions | -4.6% | 961.8K | — | — | 41.4K |
| Myles David C.CH. DISCOV. & NON-CLIN DEV OFF · 11 transactions | -8.6% | 700.4K | 100.0K | — | 161.0K |
| Rappaport AndrewDirector · 2 transactions | — | 386.0K | 35.9K | — | — |
| Bohen SeanPresident and CEO, Director · 1 transaction | -2.2% | 237.7K | — | — | — |
| Kovacs Shane William CharlesCH. OPERATING & FINANCIAL OFF. · 4 transactions | -74.3% | 139.7K | — | — | 103.8K |
| Zojwalla NaseemChief Medical Officer · 8 transactions | -19.7% | 104.0K | 140.0K | — | 269.5K |
| Austin Sasha LuVP of Finance and Controller · 1 transaction | — | 4.5K | 11.7K | — | — |
| Mitchell ShawnteCHIEF LEGAL OFFICER · 5 transactions | — | 233 | 40.0K | — | 40.0K |
| Clark Ian TDirector · 7 transactions | — | 0 | 264.8K | — | 264.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -880.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.